Tayshia said all 33 patients cleared acute safety monitoring, with no severe treatment-related serious adverse events or dose-limiting toxicities as of the November 2026 cutoff. Six-month interim data and FDA pathway feedback are expected in the first half of 2027.
TSHA · Taysha Gene Therapies, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Taysha Gene Therapies completed TSHA-102’s BLA-enabling PPQ campaign, meeting predefined specifications and comparability criteria; topline data from the REVEAL pivotal 6-month interim analysis and FDA feedback on the BLA submission pathway are expected in the first half of 2027.
Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TSHA
this stock
Taysha Gene Therapies, Inc.
|
$1.30B | -27.5% | +17.3% | — | 16.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 17
Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TSHA | -6.8% | -3.2% | -32.0% | -3.4% | -27.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -2.9% | +2.4% | -28.6% | 0.0% | -34.5% |